{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:48:53Z","timestamp":1789102133253,"version":"build-2803163510"},"reference-count":115,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1185\/030079904125003179","type":"journal-article","created":{"date-parts":[[2004,4,19]],"date-time":"2004-04-19T19:17:31Z","timestamp":1082402251000},"page":"485-504","source":"Crossref","is-referenced-by-count":30,"title":["Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literature"],"prefix":"10.1185","volume":"20","author":[{"given":"Rodrigo","family":"Martino","sequence":"first","affiliation":[{"name":"Division of Clinical Haematology, Hospital de la Santa Creu i Sant Pau, Sant Antoni Ma Claret 167, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2004,2,19]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"crossref","unstructured":"Groll AH Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect 2001;7\\(Suppl. 2):8\u201324","DOI":"10.1111\/j.1469-0691.2001.tb00005.x"},{"key":"e_1_2_1_3_1","unstructured":"Rolston K. Overview of systemic fungal infections. Oncology 2001;15\\(Suppl. 9):11\u20134"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199005020-00003"},{"key":"e_1_2_1_5_1","doi-asserted-by":"crossref","unstructured":"Gallis HA Drew RH Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12: 308\u201329","DOI":"10.1093\/clinids\/12.2.308"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.1996.32.5.379050"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.3109\/08982109809039931"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002809703101011"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(96)00075-6"},{"key":"e_1_2_1_10_1","first-page":"1","article-title":"Lipid formulations of amphotericin B","volume":"20","author":"Dix SP","year":"2000","unstructured":"Dix SP, Andriole VT. Lipid formulations of amphotericin B. Curr Clin Top Infect Dis 2000;20:1\u201323","journal-title":"Curr Clin Top Infect Dis"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/08982109309150730"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.10.2201"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.5.886"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.8.2068-2076.2000"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1179\/acb.2002.014"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199904150-00376"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1086\/514704"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.4.767"},{"key":"e_1_2_1_19_1","first-page":"1412","article-title":"Warnock DW","volume":"42","author":"Johnson EM","year":"1998","unstructured":"Johnson EM, Ojwang JO, Szekely A, Wallace TL, Warnock DW. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob Agents Chemother 1998;42:1412\u20136","journal-title":"Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob Agents Chemother"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.3109\/10611869708995847"},{"key":"e_1_2_1_21_1","first-page":"1264","article-title":"Denning DW","volume":"43","author":"Oakley KL","year":"1999","unstructured":"Oakley KL, Moore CB, Denning DW. Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole. Antimicrob Agents Chemother 1999;43:1264\u20136","journal-title":"Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole. Antimicrob Agents Chemother"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.10.2900-2902.2000"},{"key":"e_1_2_1_23_1","unstructured":"Elan Pharma Ltd. Amphotericin B lipid complex (Abelcet\u00ae): summary of product characteristics. 1 October 2001. PL: 16804\/0018"},{"key":"e_1_2_1_24_1","unstructured":"Tambyah PA Zilz MA Maki DG. A comparison of amphotericin B lipid complex (ABLC) with conventional amphotericin B for the treatment of invasive aspergillosis. 8th International Congress on Infectious Diseases; Boston Massachusetts; 15\u201318 May 1998 [Abstract 23.024]"},{"key":"e_1_2_1_25_1","first-page":"17","volume":"37","author":"Linden PK","year":"2003","unstructured":"Linden PK, Coley K, Fontes P, Fung JJ, Kusne S. Invasive aspergillosis in liver transplant recipients: comparison of therapy with amphotericin B lipid complex and a historical cohort treated with conventional amphotericin B therapy. Clin Infect Dis 2003;37:17\u201325","journal-title":"Kusne S. Invasive aspergillosis in liver transplant recipients: comparison of therapy with amphotericin B lipid complex and a historical cohort treated with conventional amphotericin B therapy. Clin Infect Dis"},{"key":"e_1_2_1_26_1","first-page":"198","article-title":"Chopra R","volume":"103","author":"Clark AD","year":"1998","unstructured":"Clark AD, McKendrick S, Tansey PJ, Franklin IM, Chopra R. A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology. Br J Haematol 1998;103:198\u2013204","journal-title":"A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology. Br J Haematol"},{"key":"e_1_2_1_27_1","first-page":"574","article-title":"Efficacy and safety of AmBisome and Abelcet in transplant patients: a multicenter study","volume":"39","author":"Fortun J","year":"1999","unstructured":"Fortun J, Munoz P, Montejo M, et al. Efficacy and safety of AmBisome and Abelcet in transplant patients: a multicenter study. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 1999;39:574","journal-title":"Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"e_1_2_1_28_1","unstructured":"Lacerda JMF Gomez B Martins C et al. Comparative analysis of liposomal (AmBisome-AMB) and lipid complex (Abelcet-ABLC) amphotericin B preparations after intensive and myeloablative chemotherapy regimens. Presented at the 41st ASH; New Orleans Louisiana; 3\u20137 December 1999 [Abstract 4438]"},{"key":"e_1_2_1_29_1","unstructured":"Tarrag\u00f3 D Fort\u00fan J Prieto MD et al. Efficacy and safety of Abelcet\u2122 and ambisome\u2122 in fungal infections after liver transplantation. Presented at the Focus on Fungal Infections 9; 17\u201319 March 1999 [Abstract 037]"},{"key":"e_1_2_1_30_1","first-page":"1155","article-title":"and the L Amph\/ABLC Collaborative Study Group","volume":"31","author":"Wingard JR","year":"2000","unstructured":"Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A, and the L Amph\/ABLC Collaborative Study Group. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000;31:1155\u201363","journal-title":"A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis"},{"key":"e_1_2_1_31_1","first-page":"1107","article-title":"Danziger LH","volume":"21","author":"Cannon JP","year":"2001","unstructured":"Cannon JP, Garey KW, Danziger LH. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacother 2001;21:1107\u201314","journal-title":"A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacother"},{"key":"e_1_2_1_32_1","first-page":"511","article-title":"Comparison of amphotericin B lipid complex (ABLC) vs","volume":"40","author":"Fleming RV","year":"2001","unstructured":"Fleming RV, Kantarjian HM, Husni R, et al. Comparison of amphotericin B lipid complex (ABLC) vs. AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leukemia Lymphoma 2001;40:511\u201320","journal-title":"AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leukemia Lymphoma"},{"key":"e_1_2_1_33_1","unstructured":"Kuti JL Kotapati S Williams P Capitano B Nightingale CH Nicolau DP. Pharmacoeconomic analysis of amphotericin B lipid complex (ABLC) versus liposomal amphotericin B (L-AmB) in the treatment of fungal infections. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 2002;42 [Abstract 0\u20131000]"},{"key":"e_1_2_1_34_1","unstructured":"Hovsepian M Lee P Goldstein B. Comparison of safety and cost-effectiveness of Abelcet\u00ae and Amphotec\u00ae. American Society of Hospital Pharmacists Las Vegas; December 1999 [poster]"},{"key":"e_1_2_1_35_1","first-page":"133","article-title":"Murray HW","volume":"127","author":"Sundar S","year":"1997","unstructured":"Sundar S, Agrawal NK, Sinha PR, Horwith GS, Murray HW. Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med 1997;127:133\u201337","journal-title":"Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med"},{"key":"e_1_2_1_36_1","first-page":"755","article-title":"Murray HW","volume":"92","author":"Sundar S","year":"1998","unstructured":"Sundar S, Goyal AK, More DK, Singh MK, Murray HW. Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex. Ann Trop Med Parasitol 1998;92:755\u201364","journal-title":"Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex. Ann Trop Med Parasitol"},{"key":"e_1_2_1_37_1","first-page":"186","article-title":"Amphotericin B lipid complex in the management of antimony-unresponsive Indian visceral leishmaniasis","volume":"47","author":"Sundar S","year":"1999","unstructured":"Sundar S, Goyal AK, Mandal AK, Makharia MK, Singh VP, Murray HW. Amphotericin B lipid complex in the management of antimony-unresponsive Indian visceral leishmaniasis. J Assoc Physicians India 1999;47:186\u20138","journal-title":"J Assoc Physicians India"},{"key":"e_1_2_1_38_1","unstructured":"Anaissie EJ White MH Uzun O et al. Amphotericin B lipid complex vs. amphotericin B for treatment of invasive candidiasis: a prospective randomized multicenter trial. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 1995;35 [Abstract 330]"},{"key":"e_1_2_1_39_1","unstructured":"Hiemenz JW Lister J Anaissie EJ et al. Emergency-use amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis: historical-control comparison with amphotericin B. Blood 1995;86\\(Suppl. 1):849a"},{"key":"e_1_2_1_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.2.315"},{"key":"e_1_2_1_41_1","unstructured":"Singletary TJ Fish DN Zamora MR Hodges TN. Safety and efficacy of amphotericin B lipid complex in thoracic transplantation. Presented at the American College of Chest Physicians; New Orleans LA; 26\u201330 October 1997 [Abstract]"},{"key":"e_1_2_1_42_1","unstructured":"Macaulay SS Martin JE Zarnke KB. Amphotericin B for the treatment of systemic fungal infections: meta-analysis of conventional versus lipid formulations. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 2002;42 (Abstract M\u2013888)"},{"key":"e_1_2_1_43_1","first-page":"1295","article-title":"Conlon C,et al","volume":"25","author":"Barrett JP","year":"2003","unstructured":"Barrett JP, Vardulaki KA, Conlon C,et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003;25:1295\u2013320","journal-title":"A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther"},{"key":"e_1_2_1_44_1","unstructured":"Sastre JL Cotallo C Colomer F Waskin H. Invasive neonatal candidiasis in Spain. Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 2000;40 [Abstract 383]"},{"key":"e_1_2_1_45_1","doi-asserted-by":"publisher","DOI":"10.1086\/516353"},{"key":"e_1_2_1_46_1","unstructured":"Ito JI with the CLEAR\u2122 Steering Committee. Results from the CLEAR\u2122 (Collaborative Exchange of Antifungal Research) program: analysis of 929 patients. Presented at the Focus on Fungal Infections 8; Orlando Florida; 4\u20136 March 1998"},{"key":"e_1_2_1_47_1","unstructured":"Kubak BM with the CLEAR Steering Committee. Salvage therapy in invasive aspergillosis with the use of amphotericin B lipid complex. Presented at the Infectious Diseases Society of America 37th Meeting; Philadelphia Pennsylvania; 18\u201321 November 1999"},{"key":"e_1_2_1_48_1","first-page":"201","article-title":"Efficacy and safety of amphotericin B lipid complex for zygomycosis","volume":"20","author":"Larkin JA","year":"2003","unstructured":"Larkin JA, Montero JA. Efficacy and safety of amphotericin B lipid complex for zygomycosis. Infect Med 2003;20:201\u20136","journal-title":"Infect Med"},{"key":"e_1_2_1_49_1","unstructured":"Baddour LM with the Collaborative Exchange of Antifungal Research (CLEAR) Steering Committee. Early response to ABLC among patients with CNS cryptococcal infections. Blood 2000;96\\(Suppl. 1):438A"},{"key":"e_1_2_1_50_1","unstructured":"Wiley JM Matera JA. Amphotericin B lipid complex (ABLC) is effective against fluconazole-resistant Candida species infections. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 2001;41 [Abstract 359]"},{"key":"e_1_2_1_51_1","first-page":"119","article-title":"Blastomycosis and histoplasmosis: early response to amphotericin B lipid complex","volume":"19","author":"Baddour LM","year":"2002","unstructured":"Baddour LM. Blastomycosis and histoplasmosis: early response to amphotericin B lipid complex. Infect Med 2002;19:119\u201321","journal-title":"Infect Med"},{"key":"e_1_2_1_52_1","first-page":"389B","article-title":"Abelcet treatment in patients who failed or were intolerant to prior Ambisome therapy","volume":"96","author":"Gelone SP","year":"2000","unstructured":"Gelone SP. Abelcet treatment in patients who failed or were intolerant to prior Ambisome therapy. Blood 2000;96:389B","journal-title":"Blood"},{"key":"e_1_2_1_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(97)00551-4"},{"key":"e_1_2_1_54_1","first-page":"329","article-title":"Chan KM","volume":"14","author":"Linden P","year":"2000","unstructured":"Linden P, Williams P, Chan KM. Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections. Clin Transplant 2000;14:329\u201339","journal-title":"Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections. Clin Transplant"},{"key":"e_1_2_1_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.4.569"},{"key":"e_1_2_1_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700842"},{"key":"e_1_2_1_57_1","unstructured":"Myint H Bolam S Orchard J et al. Amphotericin B lipid complex (ABLC) is effective in neutropenic patients with radiological evidence of pulmonary fungal infections. Presented at the 23rd Annual Meeting of the European Group for Blood and Bone Marrow Transplantation and the 13th Meeting of the Nurses Group; Aix-les-Bains France; 26 March 1997 [Abstract]"},{"key":"e_1_2_1_58_1","first-page":"417","article-title":"Winn RM","volume":"41","author":"Myint H","year":"1998","unstructured":"Myint H, Kyi AA, Winn RM. An open, non-comparative evaluation of the efficacy and safety of amphotericin B lipid complex as treatment of neutropenic patients with presumed or confirmed pulmonary fungal infections. J Antimicrob Agents Chemother 1998;41:417\u201326","journal-title":"An open, non-comparative evaluation of the efficacy and safety of amphotericin B lipid complex as treatment of neutropenic patients with presumed or confirmed pulmonary fungal infections. J Antimicrob Agents Chemother"},{"key":"e_1_2_1_59_1","first-page":"995","article-title":"Philips DL","volume":"23","author":"Sallah S","year":"1999","unstructured":"Sallah S, Semelka RC, Sallah W, Vainright JR, Philips DL. Amphotericin B lipid complex for the treatment of patients with acute leukemia and hepatosplenic candidiasis. Leuk Res 1999;23:995\u20139","journal-title":"Amphotericin B lipid complex for the treatment of patients with acute leukemia and hepatosplenic candidiasis. Leuk Res"},{"key":"e_1_2_1_60_1","first-page":"24","article-title":"Low-dose amphotericin B lipid complex (ABLC) is safe and effective as empiric antifungal therapy in immunocompromised patients with hematologic malignancies","volume":"96","author":"Mehta J","year":"2000","unstructured":"Mehta J, Powles R, Sirohi B, et al. Low-dose amphotericin B lipid complex (ABLC) is safe and effective as empiric antifungal therapy in immunocompromised patients with hematologic malignancies. Blood 2000;96:24","journal-title":"Blood"},{"key":"e_1_2_1_61_1","unstructured":"Ostronoff M Souto Maior AP Sucupira A et al. Prophylactic use of amphotericin B lipid complex (ABLC \u2013Abelcet\u00ae) in patients (pts) undergoing hematologic intensive treatment and bone marrow transplantation. Abstract from 44th American Society of Hematology 6\u201310 December 2002 (www.abstracts-online.com\/abstracts\/hemphiladelphia02\/search\/results.asp?Num = 0%2E9818644)"},{"key":"e_1_2_1_62_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.3.8.1101"},{"key":"e_1_2_1_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/173.3.762"},{"key":"e_1_2_1_64_1","unstructured":"Schaison G. Amphotericin B lipid complex (ABLC): treatment in children with invasive fungal infections. Presented at Simposium Internacional sobre Infecciones F\u00fangicas en el Reci\u00e9n Nacido; Rome Italy 6 June 1997 [Abstract]"},{"key":"e_1_2_1_65_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.9.1944"},{"key":"e_1_2_1_66_1","unstructured":"Kelly C Cornish J Marks D Pamphillon D Steward C Oakhill A. The use of amphotericin B lipid complex in unrelated donor bone marrow transplantation. Bone Marrow Transplant 1998;21\\(Suppl. 1):497"},{"key":"e_1_2_1_67_1","unstructured":"Khairy Zaki A Hamdy El sissy A. Amphotericin B lipid complex experience at the paediatric unit National Cancer Institute Cairo University. First International Congress of the Egyptian Group of Pediatric Oncology 1999 [Abstract]"},{"key":"e_1_2_1_68_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199908000-00010"},{"key":"e_1_2_1_69_1","unstructured":"Wiley JM Walsh TJ Matera JA. The use of amphotericin B lipid complex in pediatric cancer patients with invasive fungal infections. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 2000;40 [Abstract 390]"},{"key":"e_1_2_1_70_1","first-page":"77","article-title":"Andr\u00e9s E,et al","volume":"20","author":"Herbrecht R","year":"2001","unstructured":"Herbrecht R, Auvrignon A, Andr\u00e9s E,et al. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients. Eur J Clin Microbiol Infect Dis 2001;20:77\u201382","journal-title":"Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients. Eur J Clin Microbiol Infect Dis"},{"key":"e_1_2_1_71_1","doi-asserted-by":"publisher","DOI":"10.1136\/fn.84.2.F131"},{"key":"e_1_2_1_72_1","first-page":"1198","article-title":"al","volume":"33","author":"Adler-Shohet FC","year":"2001","unstructured":"Adler-Shohet FC, Arrieta AC, Ross LA, et al. Amphotericin B lipid complex in neonates with invasive candidiasis. Clin Infect Dis 2001;33:1198","journal-title":"Amphotericin B lipid complex in neonates with invasive candidiasis. Clin Infect Dis"},{"key":"e_1_2_1_73_1","unstructured":"Chisholm JC Devine T Mycroft J Pinkerton CR. Tolerability of amphotericin B lipid complex (Abelcet) in children with malignant disease. Bone Marrow Transplant 1998;21\\(Suppl. 1):S145 [Abstract 502]"},{"key":"e_1_2_1_74_1","unstructured":"Allsup D Chu P. A single centre analysis of the risk of nephrotoxicity and the efficacy of amphotericin B lipid complex for the treatment of suspected or proven fungal infections in patients receiving treatment for haematological malignancies. Presented at Trends in Invasive Infections 4; Barcelona Spain; 5\u20138 November 1997"},{"key":"e_1_2_1_75_1","unstructured":"Herzig R. Experience with amphotericin B lipid complex injection in the treatment of infectious complications after peripheral stem cell transplantation. Blood 1997;90\\(Suppl. 1 pt 2 of 2):369b"},{"key":"e_1_2_1_76_1","unstructured":"Seymour JF Szer J Grigg AP Bardy P. Efficacy and toxicity of amphotericin B lipid complex (ABLC \u2013 Abelcet\u2122) in patients with hematologic malignancies and invasive fungal infections failing standard therapy. Blood 1997;90\\(Suppl. 1 pt 2 of 2):56b"},{"key":"e_1_2_1_77_1","first-page":"1097","article-title":"Rodman JH","volume":"17","author":"Stevens RC","year":"1997","unstructured":"Stevens RC, McCormick JN, Rodman JH. Tolerance of amphotericin B lipid complex in pediatric cancer patients. Pharmacology 1997;17:1097","journal-title":"Tolerance of amphotericin B lipid complex in pediatric cancer patients. Pharmacology"},{"key":"e_1_2_1_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(98)70046-0"},{"key":"e_1_2_1_79_1","unstructured":"Aguado JM Gonz\u00e1lez D on behalf of the ABLC Pharmacosurveillance Study Group. Low nephrotoxicity in patients receiving amphotericin B lipid complex (ABLC). A pharmacosurveillance study in Spain. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 2000;40 [Abstract 390]"},{"key":"e_1_2_1_80_1","unstructured":"Stalder T Waskin H Anderson A Spurzem J Dominguez E. High-dose amphotericin B lipid complex (ABLC) for treatment of invasive aspergillosis and zygomycosis. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 1998;38 [Abstract 489]"},{"key":"e_1_2_1_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701406"},{"key":"e_1_2_1_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701824"},{"key":"e_1_2_1_83_1","first-page":"116","article-title":"Mutimer DJ","volume":"24","author":"Singhal S","year":"1999","unstructured":"Singhal S, Hastings JGM, Mutimer DJ. Safety of high-dose amphotericin B lipid complex. Bone Marrow Transplant 1999;24:116\u20137","journal-title":"Safety of high-dose amphotericin B lipid complex. Bone Marrow Transplant"},{"key":"e_1_2_1_84_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702156"},{"key":"e_1_2_1_85_1","unstructured":"Gibson G Edden M Kasbekar N Morgan A Fishman N. Evaluation of adverse events associated with two lipid amphotericin products in patients who experience or are at risk to amphotericin B adverse events. Presented at the Focus on Fungal Infections 8; Orlando Florida; 4\u20136 March 1998 [Abstract 021]"},{"key":"e_1_2_1_86_1","doi-asserted-by":"publisher","DOI":"10.1086\/342563"},{"key":"e_1_2_1_87_1","doi-asserted-by":"crossref","unstructured":"Matot I Pizov R. Pulmonary extraction and accumulation of lipid formulations of amphotericin B. Crit Care Med 2000;28(7):2528\u201332 87.","DOI":"10.1097\/00003246-200007000-00056"},{"key":"e_1_2_1_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)80066-2"},{"key":"e_1_2_1_89_1","unstructured":"Salazar R Peters J Levine S et al. Evaluation of renal toxicity of amphotericin B lipid complex (ABLC) in solid organ transplant (SOT) patients. Am J Respir Crit Care Med 1999; 159(Suppl.):A537"},{"key":"e_1_2_1_90_1","unstructured":"Leather HL Matera J Waskins H Wingard JR. Rates of nephrotoxicity in patients receiving amphotericin B lipid complex (ABLC): comparison between allogeneic BMT recipients with all patients given ABLC. Blood 1999;94\\(Suppl. 1 pt 2):369b"},{"key":"e_1_2_1_91_1","doi-asserted-by":"crossref","unstructured":"Singhal S Hastings JGM Mutimer DJ. Safety of high-dose amphotericin B lipid complex (Abelcet) in patients with liver disease. J Hepatol 1999;30\\(Suppl. 1):174","DOI":"10.1038\/sj.bmt.1701829"},{"key":"e_1_2_1_92_1","unstructured":"Strickland J Yee G Lister J Lee L Wingard J Lee H. Nephrotoxicity of amphotericin B lipid complex in bone marrow transplant patients receiving cyclosporine. Pharmacother 1999;19:504 [Abstract 169]"},{"key":"e_1_2_1_93_1","unstructured":"Barron RL Kazakoff PW Gabel I Madinger NE. Novel hepatotoxicity of amphotericin B lipid complex in combination with cyclosporine a. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 1997;37 [Abstract 375]"},{"key":"e_1_2_1_94_1","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/j.1875-9114.1998.tb03915.x","article-title":"Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B","volume":"18","author":"Barcia JP","year":"1998","unstructured":"Barcia JP. Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B. Pharmacotherapy 1998;18:874\u20136","journal-title":"Pharmacotherapy"},{"key":"e_1_2_1_95_1","doi-asserted-by":"publisher","DOI":"10.1086\/313533"},{"key":"e_1_2_1_96_1","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1086\/322668","article-title":"Pulmonary reactions during treatment with amphotericin B: review of published cases and guidelines for management","volume":"33","author":"Collazos J","year":"2001","unstructured":"Collazos J, Mart\u00ednez E, Mayo J, Ibarra S. Pulmonary reactions during treatment with amphotericin B: review of published cases and guidelines for management. Clin Infect Dis 2001;33:e75\u201382","journal-title":"Clin Infect Dis"},{"key":"e_1_2_1_97_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200108150-00036"},{"key":"e_1_2_1_98_1","unstructured":"Drew RH Palmer SM Davis R Perfect JR. Invasive fungal infections (IFIs) in lung transplant recipients (LTR) receiving prophylactic aerosolized amphotericin B (aAmB) formulations. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 2002;42 [Abstract M\u201312360]"},{"key":"e_1_2_1_99_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000054233.60100.7A"},{"key":"e_1_2_1_100_1","unstructured":"Anderson N Drew R Hayward S Perfect J Dukes Hamilton C. A successful program to optimize use of amphotericin B lipid complex (ABLC) at an academic medical center. Presented at the 35th Annual Meeting of the Infectious Diseases Society of America; San Francisco California; 13\u201316 September 1997 [Abstract 151]"},{"key":"e_1_2_1_101_1","unstructured":"Lapointe AK Calandra T Bille J Glauser MP Marchetti O. A 10-year review of the use of amphotericin B (AmB) in adult neutropenic cancer patients (Pt) in an university hospital. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 2000;40 [Abstract 390]"},{"key":"e_1_2_1_102_1","unstructured":"Chan S Forrest GN Kleinberg M Donnenberg MS Standiford HC. Significant cost savings with implementation of lipid amphotericin B (L.A.B.). Guidelines in a university cancer center. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 2002;42 [Abstract O-999 and poster]"},{"key":"e_1_2_1_103_1","unstructured":"Goff DA Sierawski SJ. A clinical and economic analysis of amphotericin B lipid complex (ABLC) versus amphotericin B. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 1998;38 [Abstract 606]"},{"key":"e_1_2_1_104_1","unstructured":"Greenberg RN Cagnoni PJ Prendergast MM Tong KB. Pharmacoeconomics of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of persistently febrile neutropenic patients. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 2000;40 [Abstract 506]"},{"key":"e_1_2_1_105_1","unstructured":"Baddour L with the CLEAR Steering Committee. Dosing experience with amphotericin B lipid complex (ABLC). Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 1999;39 [Abstract 573]"},{"key":"e_1_2_1_106_1","unstructured":"Powles R Sirohi B Mehta J et al. Low-dose amphotericin B lipid complex (ABLC) is safe and effective as empiric anti-fungal therapy in immunocompromised patients with hematologic malignancies. Presented at the 27th Annual Meeting European Group for Blood and Marrow Transplantation and 17th Nurses Group Meeting; Maastricht The Netherlands; 25\u201328 March 2001 [Abstract]"},{"key":"e_1_2_1_107_1","first-page":"505","article-title":"al","volume":"23","author":"Subir\u00e0 M","year":"2001","unstructured":"Subir\u00e0 M, Martino R, Sureda A, et al. Safety and efficacy of low-dose amphotericin B lipid complex for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies. Methods Find Exp Clin Pharmacol 2001;23:505\u201310","journal-title":"Safety and efficacy of low-dose amphotericin B lipid complex for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies. Methods Find Exp Clin Pharmacol"},{"key":"e_1_2_1_108_1","unstructured":"Rogers J Conway A. Tolerability of low dose amphotericin B lipid complex (Abelcet\u00ae) for the treatment of pyrexia of unknown origin (PUO) in neutropenic cancer patients. Bone Marrow Transplant 1998;21\\(Suppl. 1):493"},{"key":"e_1_2_1_109_1","unstructured":"Cook G Lever M Tansey P et al. Low dose amphotericin B lipid complex (Abelcet) is effective in the treatment of neutropenic pyrexia of unknown origin. Presented at the Fourth Congress of the European Haematology Association; Barcelona Spain 9\u201312 June 1999 (P0\u20130955)"},{"key":"e_1_2_1_110_1","unstructured":"Myint H Bolam S Kyi AA Creasy T. Prevention of recurrence of fungal pneumonia with prophylactic low dose amphotericin B lipid complex (Abelcet) following myelosuppressive chemotherapy. Presented at the 23rd Annual Meeting of the European Group for Blood and Bone Marrow Transplantation and the 13th Meeting of the Nurses Group; Aix-les-Bains France; 26 March 1997 [Abstract]"},{"key":"e_1_2_1_111_1","unstructured":"Myint H Hall R Bolam S Kyi AA Winn R. Pre-emptive therapy with low dose amphotericin B lipid complex (ABELCET) prevents recurrence of fungal pneumonia in immuno-compromised patients. Blood 1998;92\\(Suppl. 1):4447"},{"key":"e_1_2_1_112_1","unstructured":"Hall R Bolam S Kyi AA Myint H. Prevention of recurrent fungal pneumonia with low dose amphotericin B lipid complex (Abelcet) in immunocompromised patients. Br J Haematol 1998;101\\(Suppl. 1):60"},{"key":"e_1_2_1_113_1","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2000.7572"},{"key":"e_1_2_1_114_1","unstructured":"Chandrasekar PH Cutright JL Manavathu EK. In vitro activity of amphotericin B lipid complex in 2-drug combination with caspofungin against Aspergillus fumigatus. Presented at the 12th Focus on Fungal Infection Meeting 20\u201322 March 2002 (http:\/\/www.doctorfungus.org\/educatio\/conf_highlights\/focus12 \/pdf\/focus_9.pdf)"},{"key":"e_1_2_1_115_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.1998.tb00668.x"},{"key":"e_1_2_1_116_1","doi-asserted-by":"crossref","unstructured":"Subir\u00e0 M Martino R G\u00f3mez L Mart\u00ed JM Estany C Sierra J. Low-dose amphotericin B lipid complex versus conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematological malignancies. A randomized controlled trial. Eur J Haematol 2004 (in press)","DOI":"10.1111\/j.1600-0609.2004.00239.x"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/030079904125003179","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T20:36:47Z","timestamp":1769719007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1185\/030079904125003179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2,19]]},"references-count":115,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["10.1185\/030079904125003179"],"URL":"https:\/\/doi.org\/10.1185\/030079904125003179","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,2,19]]}}}